Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

CHA2DS2-VASc score use in sinus rhythm: Can it predict cardiovascular events?

Chousou PA, Pugh PJ, Vassiliou VS.

Eur J Prev Cardiol. 2019 Dec;26(18):1985-1986. doi: 10.1177/2047487319872020. Epub 2019 Aug 29. No abstract available.

PMID:
31466472
2.

Managing anticoagulation in patients receiving implantable cardiac devices.

Chousou PA, Pugh PJ.

Future Cardiol. 2018 Mar;14(2):151-164. doi: 10.2217/fca-2017-0044. Epub 2017 Dec 11.

PMID:
29226707
3.

How to deliver optimal cardiac resynchronisation therapy.

Chousou PA, Pugh PJ.

Heart. 2018 Aug;104(15):1300-1307. doi: 10.1136/heartjnl-2017-311210. Epub 2017 Dec 7. No abstract available.

PMID:
29217631
4.

An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease.

Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, Jones PS, Rowe JB, Rubinsztein DC, Barker RA.

J Neurol. 2017 Dec;264(12):2457-2463. doi: 10.1007/s00415-017-8647-0. Epub 2017 Oct 26.

5.

Pericardial actinomycosis in a patient with oesophageal dysmotility and autoantibodies.

Bellanti R, Chousou PA, Pugh PJ.

Br J Hosp Med (Lond). 2017 Aug 2;78(8):472-473. doi: 10.12968/hmed.2017.78.8.472. No abstract available.

PMID:
28783393
6.

Holiday Shocker: An Unusual Cause of Implantable Cardioverter Defibrillator Therapy.

Carpenter V, Pugh PJ, Martin CA.

Pacing Clin Electrophysiol. 2015 Sep;38(9):1114-6. doi: 10.1111/pace.12583. Epub 2015 Jan 28. No abstract available.

PMID:
25627877
7.

Development of a multiparametric score to predict left ventricular remodelling and prognosis after cardiac resynchronization therapy.

Kydd AC, Khan FZ, Ring L, Pugh PJ, Virdee MS, Dutka DP.

Eur J Heart Fail. 2014 Nov;16(11):1206-13. doi: 10.1002/ejhf.167. Epub 2014 Oct 10.

8.
9.

Safety of the colonoscope magnetic imaging device (ScopeGuide) in patients with implantable cardiac devices.

Corbett GD, Lim YC, Lee JC, Chernolesskiy A, Pugh PJ, Cameron EA.

Endoscopy. 2014 Feb;46(2):135-8. doi: 10.1055/s-0033-1359044. Epub 2014 Jan 29.

PMID:
24477369
10.

Unusual cause of poor response to cardiac resynchronisation therapy.

Martin CA, Gajendragadkar PR, Pugh PJ.

Heart. 2014 Mar;100(6):514. doi: 10.1136/heartjnl-2013-305340. Epub 2014 Jan 6. No abstract available.

PMID:
24395978
11.

Eligibility for cardiac resynchronisation therapy among patients with heart failure, according to UK NICE guideline criteria.

Nayar V, Hiari N, Prasad R, Belham MR, Dutka DP, Pugh PJ.

Int J Cardiol. 2013 Oct 9;168(4):4401-2. doi: 10.1016/j.ijcard.2013.05.041. Epub 2013 May 22. No abstract available.

PMID:
23706281
12.

Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke.

Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ.

Neurology. 2013 Apr 23;80(17):1546-50. doi: 10.1212/WNL.0b013e31828f1828. Epub 2013 Mar 27.

13.

Radial strain delay based on segmental timing and strain amplitude predicts left ventricular reverse remodeling and survival after cardiac resynchronization therapy.

Kydd AC, Khan FZ, O'Halloran D, Pugh PJ, Virdee MS, Dutka DP.

Circ Cardiovasc Imaging. 2013 Mar 1;6(2):177-84. doi: 10.1161/CIRCIMAGING.112.000191. Epub 2013 Jan 30.

PMID:
23363579
14.

Managing anticoagulation in patients receiving implantable cardiac devices.

Mangrolia N, Nayar V, Pugh PJ.

Future Cardiol. 2012 May;8(3):393-411. Review.

PMID:
26203472
15.

Endoscopy and implantable electronic devices.

Corbett GD, Buttery PC, Pugh PJ, Cameron EAB.

Frontline Gastroenterol. 2012 Apr;3(2):72-75. doi: 10.1136/flgastro-2011-100010. Epub 2012 Feb 5. Review.

16.

Stressed at the dentist? A case of tako-tsubo.

Vassiliou V, Ladwiniec A, Pugh PJ.

Cardiol J. 2012;19(2):205-6. No abstract available.

17.

Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial.

Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP.

J Am Coll Cardiol. 2012 Apr 24;59(17):1509-18. doi: 10.1016/j.jacc.2011.12.030. Epub 2012 Mar 7.

18.

Drug and device therapy for patients with chronic heart failure.

Prasad R, Pugh PJ.

Expert Rev Cardiovasc Ther. 2012 Mar;10(3):313-5. doi: 10.1586/erc.12.2.

PMID:
22390803
19.

Cardiac resynchronization therapy optimization using noninvasive cardiac output measurement.

Khan FZ, Virdee MS, Hutchinson J, Smith B, Pugh PJ, Read PA, Fynn SP, Dutka DP.

Pacing Clin Electrophysiol. 2011 Nov;34(11):1527-36. doi: 10.1111/j.1540-8159.2011.03172.x.

PMID:
21797899
20.

Optimizing atrioventricular and interventricular intervals following cardiac resynchronization therapy.

Nayar V, Khan FZ, Pugh PJ.

Expert Rev Cardiovasc Ther. 2011 Feb;9(2):185-97. doi: 10.1586/erc.10.187. Review.

PMID:
21453215
21.

Impact of VV optimization in relation to left ventricular lead position: an acute haemodynamic study.

Khan FZ, Virdee MS, Read PA, Pugh PJ, Begley D, Fynn SP, Dutka DP.

Europace. 2011 Jun;13(6):845-52. doi: 10.1093/europace/eur037. Epub 2011 Mar 21.

22.

The impact of the right ventricular lead position on response to cardiac resynchronization therapy.

Khan FZ, Salahshouri P, Duehmke R, Read PA, Pugh PJ, Elsik M, Begley D, Fynn SP, Dutka DP, Virdee MS.

Pacing Clin Electrophysiol. 2011 Apr;34(4):467-74. doi: 10.1111/j.1540-8159.2010.02995.x. Epub 2011 Jan 5.

PMID:
21208234
23.

Increased incidence of interatrial block in younger adults with cryptogenic stroke and patent foramen ovale.

Cotter PE, Martin PJ, Pugh PJ, Warburton EA, Cheriyan J, Belham M.

Cerebrovasc Dis Extra. 2011 Jan-Dec;1(1):36-43. doi: 10.1159/000327346. Epub 2011 Apr 14.

24.

Low serum testosterone and increased mortality in men with coronary heart disease.

Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS.

Heart. 2010 Nov;96(22):1821-5. doi: 10.1136/hrt.2010.195412. Epub 2010 Oct 19.

PMID:
20959649
25.

Recurrence of B-cell lymphoma within an implantable cardioverter defibrillator wound scar.

Nayar V, Wright P, Pugh PJ.

Europace. 2011 Mar;13(3):443-4. doi: 10.1093/europace/euq367. Epub 2010 Oct 14.

PMID:
20947569
26.

Effect of low-amplitude two-dimensional radial strain at left ventricular pacing sites on response to cardiac resynchronization therapy.

Khan FZ, Virdee MS, Read PA, Pugh PJ, O'Halloran D, Fahey M, Elsik M, Begley D, Fynn SP, Dutka DP.

J Am Soc Echocardiogr. 2010 Nov;23(11):1168-76. doi: 10.1016/j.echo.2010.08.023.

PMID:
20888187
27.

A fungal pathogen in time and space: the population dynamics of Beauveria bassiana in a conifer forest.

Ormond EL, Thomas AP, Pugh PJ, Pell JK, Roy HE.

FEMS Microbiol Ecol. 2010 Oct;74(1):146-54. doi: 10.1111/j.1574-6941.2010.00939.x. Epub 2010 Jul 20.

28.

Coronary veno-venous malformation: a new anomaly?

Lee JM, Pugh PJ.

Europace. 2010 Sep;12(9):1295. doi: 10.1093/europace/euq188. Epub 2010 Jun 20. No abstract available.

PMID:
20566480
29.

Hepatocellular carcinoma presenting as right heart failure.

Nayar V, Singh B, Pugh PJ.

Eur Heart J. 2010 Aug;31(16):1957. doi: 10.1093/eurheartj/ehq147. Epub 2010 May 21. No abstract available.

PMID:
20494904
30.

Cardiac resynchronization therapy for the treatment of heart failure.

Nayar V, Pugh PJ.

Expert Rev Cardiovasc Ther. 2010 Feb;8(2):229-39. doi: 10.1586/erc.10.1. Review. Erratum in: Expert Rev Cardiovasc Ther. 2010 Jul;8(7):1040-2.

PMID:
20136609
31.

Non-invasive cardiac output measurements based on bioreactance for optimization of atrio- and interventricular delays.

Khan FZ, Virdee MS, Pugh PJ, Read PA, Fynn SP, Dutka DP.

Europace. 2009 Dec;11(12):1666-74. doi: 10.1093/europace/eup358. Epub 2009 Nov 11.

PMID:
19910316
32.

Testosterone acts as an efficacious vasodilator in isolated human pulmonary arteries and veins: evidence for a biphasic effect at physiological and supra-physiological concentrations.

Rowell KO, Hall J, Pugh PJ, Jones TH, Channer KS, Jones RD.

J Endocrinol Invest. 2009 Oct;32(9):718-23. doi: 10.3275/6361.

PMID:
19535892
33.

Perils of weight loss: the advantage of being obese in patients with heart failure.

Kydd A, Pugh PJ.

Expert Rev Cardiovasc Ther. 2009 Mar;7(3):263-7. doi: 10.1586/14779072.7.3.263.

PMID:
19296763
34.

Antarctic terrestrial life--challenging the history of the frozen continent?

Convey P, Gibson JA, Hillenbrand CD, Hodgson DA, Pugh PJ, Smellie JL, Stevens MI.

Biol Rev Camb Philos Soc. 2008 May;83(2):103-17. doi: 10.1111/j.1469-185X.2008.00034.x. Review.

PMID:
18429764
35.

Successful internal defibrillation following unusual positioning of defibrillator lead.

Pugh PJ, Clague JR.

Europace. 2008 Jul;10(7):895-6. doi: 10.1093/europace/eun047. Epub 2008 Mar 3. No abstract available.

PMID:
18319267
36.

Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease.

Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD.

Horm Metab Res. 2007 May;39(5):366-71.

PMID:
17533579
37.

Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure.

Pugh PJ, Jones RD, Malkin CJ, Hall J, Nettleship JE, Kerry KE, Jones TH, Channer KS.

Endocr Res. 2005;31(4):271-83.

PMID:
16433247
38.

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.

Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS.

Eur Heart J. 2006 Jan;27(1):57-64. Epub 2005 Aug 10.

PMID:
16093267
39.

An uncommon cause of aortic stenosis in an adult.

Pugh PJ, Latib A, Ntsekhe M, Commerford PJ.

Heart. 2005 Aug;91(8):1018. No abstract available.

40.

Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life.

Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS.

Heart. 2004 Aug;90(8):871-6.

41.

The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.

Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH.

J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8.

PMID:
15240608
42.

Testosterone treatment for men with chronic heart failure.

Pugh PJ, Jones RD, West JN, Jones TH, Channer KS.

Heart. 2004 Apr;90(4):446-7. No abstract available.

43.

Effect of testosterone therapy on QT dispersion in men with heart failure.

Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS.

Am J Cardiol. 2003 Nov 15;92(10):1241-3.

PMID:
14609611
44.

Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability.

Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS.

J Endocrinol. 2003 Sep;178(3):373-80. Review.

PMID:
12967330
45.

Testosterone for secondary prevention in men with ischaemic heart disease?

Malkin CJ, Pugh PJ, Jones TH, Channer KS.

QJM. 2003 Jul;96(7):521-9. Review. No abstract available.

PMID:
12881595
46.

Acute haemodynamic effects of testosterone in men with chronic heart failure.

Pugh PJ, Jones TH, Channer KS.

Eur Heart J. 2003 May;24(10):909-15.

PMID:
12714022
47.

The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action?

Jones RD, Pugh PJ, Jones TH, Channer KS.

Br J Pharmacol. 2003 Mar;138(5):733-44. Review. No abstract available.

48.

Cytomegalovirus seropositivity, infectious burden, and coronary artery disease.

Pugh PJ, Malkin CJ, Channer KS.

Am Heart J. 2003 Feb;145(2):e11. No abstract available.

PMID:
12599385
49.
50.

Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse.

Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH.

Eur J Endocrinol. 2003 Jan;148(1):111-20.

PMID:
12534364

Supplemental Content

Support Center